FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899609741> ?p ?o ?g. }

• W2899609741 endingPage "482" @default.
• W2899609741 startingPage "472" @default.
• W2899609741 abstract "Telemedicine has shown promise in inflammatory bowel disease (IBD). The objective of this study was to compare disease activity and quality of life (QoL) in a 1-year randomized trial of IBD patients receiving telemedicine vs. standard care.Patients with worsening symptoms in the prior 2 years were eligible for randomization to telemedicine (monitoring via texts EOW or weekly) or standard care. The primary outcomes were the differences in change in disease activity and QoL between the groups; change in healthcare utilization among groups was a secondary aim.348 participants were enrolled (117 control group, 115 TELE-IBD EOW, and 116 TELE-IBD weekly). 259 (74.4%) completed the study. Age was 38.9 ± 12.3 years, 56.6% were women, 91.9% were Caucasian, 67.9% had Crohn's disease (CD) and 42.5% had active disease at baseline. In CD, all groups experienced a decrease in disease activity (control -5.2 ± 5.0 to 3.7 ± 3.6, TELE-IBD EOW 4.7 ± 4.1 to 4.2 ± 3.9, and TELE-IBD weekly 4.2 ± 4.2 to 3.2 ± 3.4, p < 0.0001 for each of the groups) In UC, only controls had a significant decrease in disease activity (control 2.9 ± 3.1 to 1.4 ± 1.4, p = 0.01, TELE-IBD EOW 2.7 ± 3.1 to 1.7 ± 1.9, p = 0.35, and TELE-IBD Weekly 2.5 ± 2.5 to 2.0 ± 1.8, p = 0.31). QoL increased in all groups; the increase was significant only in TELE-IBD EOW (control 168.1 ± 34.0 to 179.3 ± 28.2, p = 0.06, TELE-IBD EOW 172.3 ± 33.1 to 181.5 ± 28.2, p = 0.03, and TELE-IBD Weekly 172.3 ± 34.5 to 179.2 ± 32.8, p = 0.10). Unadjusted and adjusted changes in disease activity and QoL were not significantly different among groups. Healthcare utilization increased in all groups. TELE-IBD weekly were less likely to have IBD-related hospitalizations and more likely to have non-invasive diagnostic tests and electronic encounters compared to controls; both TELE-IBD groups had decreased non-IBD related hospitalizations and increased telephone calls compared to controls.Disease activity and QoL, although improved in all participants, were not improved further through use of the TELE-IBD system. TELE-IBD participants experienced a decrease in hospitalizations with an associated increase in non-invasive diagnostic tests, telephone calls and electronic encounters. Research is needed to determine if TELE-IBD can be improved through patient engagement and whether it can decrease healthcare utilization by replacing standard care." @default.
• W2899609741 created "2018-11-16" @default.
• W2899609741 creator A5002303350 @default.
• W2899609741 creator A5004571098 @default.
• W2899609741 creator A5010286432 @default.
• W2899609741 creator A5024425226 @default.
• W2899609741 creator A5030162901 @default.
• W2899609741 creator A5030532806 @default.
• W2899609741 creator A5033328354 @default.
• W2899609741 creator A5036406384 @default.
• W2899609741 creator A5055641523 @default.
• W2899609741 creator A5057963537 @default.
• W2899609741 creator A5064989322 @default.
• W2899609741 creator A5075740809 @default.
• W2899609741 creator A5077972812 @default.
• W2899609741 creator A5078901321 @default.
• W2899609741 creator A5084044892 @default.
• W2899609741 creator A5089683510 @default.
• W2899609741 creator A5089992547 @default.
• W2899609741 date "2018-11-08" @default.
• W2899609741 modified "2023-10-02" @default.
• W2899609741 title "A Randomized Controlled Trial of TELEmedicine for Patients with Inflammatory Bowel Disease (TELE-IBD)" @default.
• W2899609741 cites W1607808246 @default.
• W2899609741 cites W1671682816 @default.
• W2899609741 cites W1975798359 @default.
• W2899609741 cites W1983310013 @default.
• W2899609741 cites W1984791073 @default.
• W2899609741 cites W1997014268 @default.
• W2899609741 cites W1997329576 @default.
• W2899609741 cites W2006322353 @default.
• W2899609741 cites W2022661087 @default.
• W2899609741 cites W2024959214 @default.
• W2899609741 cites W2025144415 @default.
• W2899609741 cites W2033944259 @default.
• W2899609741 cites W2036529637 @default.
• W2899609741 cites W2037945988 @default.
• W2899609741 cites W2045532520 @default.
• W2899609741 cites W2057003221 @default.
• W2899609741 cites W2065637841 @default.
• W2899609741 cites W2066244236 @default.
• W2899609741 cites W2069528603 @default.
• W2899609741 cites W2070065759 @default.
• W2899609741 cites W2078533920 @default.
• W2899609741 cites W2104157678 @default.
• W2899609741 cites W2105311242 @default.
• W2899609741 cites W2108332624 @default.
• W2899609741 cites W2112157563 @default.
• W2899609741 cites W2123485165 @default.
• W2899609741 cites W2126807394 @default.
• W2899609741 cites W2164282046 @default.
• W2899609741 cites W2169655565 @default.
• W2899609741 cites W2255357183 @default.
• W2899609741 cites W2556960393 @default.
• W2899609741 cites W2734356183 @default.
• W2899609741 cites W4295333203 @default.
• W2899609741 doi "https://doi.org/10.1038/s41395-018-0272-8" @default.
• W2899609741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30410041" @default.
• W2899609741 hasPublicationYear "2018" @default.
• W2899609741 type Work @default.
• W2899609741 sameAs 2899609741 @default.
• W2899609741 citedByCount "102" @default.
• W2899609741 countsByYear W28996097412019 @default.
• W2899609741 countsByYear W28996097412020 @default.
• W2899609741 countsByYear W28996097412021 @default.
• W2899609741 countsByYear W28996097412022 @default.
• W2899609741 countsByYear W28996097412023 @default.
• W2899609741 crossrefType "journal-article" @default.
• W2899609741 hasAuthorship W2899609741A5002303350 @default.
• W2899609741 hasAuthorship W2899609741A5004571098 @default.
• W2899609741 hasAuthorship W2899609741A5010286432 @default.
• W2899609741 hasAuthorship W2899609741A5024425226 @default.
• W2899609741 hasAuthorship W2899609741A5030162901 @default.
• W2899609741 hasAuthorship W2899609741A5030532806 @default.
• W2899609741 hasAuthorship W2899609741A5033328354 @default.
• W2899609741 hasAuthorship W2899609741A5036406384 @default.
• W2899609741 hasAuthorship W2899609741A5055641523 @default.
• W2899609741 hasAuthorship W2899609741A5057963537 @default.
• W2899609741 hasAuthorship W2899609741A5064989322 @default.
• W2899609741 hasAuthorship W2899609741A5075740809 @default.
• W2899609741 hasAuthorship W2899609741A5077972812 @default.
• W2899609741 hasAuthorship W2899609741A5078901321 @default.
• W2899609741 hasAuthorship W2899609741A5084044892 @default.
• W2899609741 hasAuthorship W2899609741A5089683510 @default.
• W2899609741 hasAuthorship W2899609741A5089992547 @default.
• W2899609741 hasConcept C126322002 @default.
• W2899609741 hasConcept C159110408 @default.
• W2899609741 hasConcept C160735492 @default.
• W2899609741 hasConcept C162324750 @default.
• W2899609741 hasConcept C168563851 @default.
• W2899609741 hasConcept C1862650 @default.
• W2899609741 hasConcept C204243189 @default.
• W2899609741 hasConcept C2778260677 @default.
• W2899609741 hasConcept C2779134260 @default.
• W2899609741 hasConcept C2779280984 @default.
• W2899609741 hasConcept C2779891985 @default.
• W2899609741 hasConcept C2779951463 @default.
• W2899609741 hasConcept C50522688 @default.
• W2899609741 hasConcept C71924100 @default.

• next